LALPATHLAB vs SURAKSHA: Stock Comparison
DR. LAL PATH LABS is the larger company by market capitalisation. DR. LAL PATH LABS shows a higher ROE, a higher dividend yield and lower leverage, while SURAKSHA DIAGNOSTIC shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
LALPATHLAB leads 9; SURAKSHA leads 4 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | LALPATHLAB | SURAKSHA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Healthcare Service Provider | Healthcare Service Provider |
Price
| Metric | LALPATHLAB | SURAKSHA |
|---|---|---|
| Live Price | ₹1,993 | ₹341.7 |
| Day Change | -0.79% | 0.21% |
| Volume | 1.45 L | 1.26 L |
| 52-Week High | ₹3,309.2 | ₹384 |
| 52-Week Low | ₹1,272.6 | ₹224.1 |
| Distance from 52W High | -39.77% | -11.02% |
Valuation
| Metric | LALPATHLAB | SURAKSHA |
|---|---|---|
| Market Cap | ₹33,301 Cr | ₹1,801 Cr |
| P/E Ratio | 57.01x | 43.06x |
| P/B Ratio | 12.11x | 6.52x |
| EPS | ₹11.45 | ₹2.5 |
| Book Value | ₹151.4 | ₹46.75 |
| Dividend Yield | 0.63% | 0.29% |
Growth
| Metric | LALPATHLAB | SURAKSHA |
|---|---|---|
| Revenue Growth (TTM YoY) | 16.6% | 31.2% |
| EPS Growth (TTM YoY) | -15.4% | -5.4% |
| Qtr Sales Growth | 9.55% | 0% |
| Qtr Profit Growth | 13.72% | 0% |
Profitability & Leverage
| Metric | LALPATHLAB | SURAKSHA |
|---|---|---|
| ROE | 20.06% | 13.64% |
| ROCE | 24.86% | 15.19% |
| Net Margin | 18.27% | 10.37% |
| Operating Margin | 25.04% | 19.81% |
| Debt to Equity | 0x | 0.01x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | LALPATHLAB | SURAKSHA |
|---|---|---|
| Promoter Holding | 51.09%▼ 0.26 pp | 49.1% |
| FII Holding | 18.73%▲ 1.37 pp | 13.97%▲ 0.5 pp |
| DII Holding | 21.58%▼ 0.01 pp | 21.56%▼ 1.67 pp |
| Public Holding | 6.35%▼ 1.12 pp | 15.37%▲ 1.16 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: DR. LAL PATH LABS and SURAKSHA DIAGNOSTIC.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.

